BioMarin Pharmaceutical Inc. (BIT:1BMRN)
Italy
· Delayed Price · Currency is EUR 54.82
0.00 (0.00%)
Last updated: Mar 4, 2026, 9:00 AM CET
BioMarin Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,221 | 2,854 | 2,419 | 2,096 | 1,846 | Upgrade
|
| Revenue Growth (YoY) | 12.87% | 17.97% | 15.42% | 13.53% | -0.76% | Upgrade
|
| Cost of Revenue | 598.23 | 580.24 | 532.06 | 1,153 | 1,099 | Upgrade
|
| Gross Profit | 2,623 | 2,274 | 1,887 | 943.41 | 746.97 | Upgrade
|
| Selling, General & Admin | 1,031 | 1,009 | 892.41 | 823.24 | 759.38 | Upgrade
|
| Research & Development | 921.93 | 747.18 | 746.77 | - | - | Upgrade
|
| Amortization of Goodwill & Intangibles | 19.39 | 43.26 | 62.21 | 65.49 | 61.91 | Upgrade
|
| Operating Expenses | 1,972 | 1,799 | 1,701 | 888.73 | 821.28 | Upgrade
|
| Operating Income | 650.73 | 474.21 | 185.77 | 54.68 | -74.32 | Upgrade
|
| Interest Expense | -10.9 | -12.67 | -17.34 | -15.97 | -15.34 | Upgrade
|
| Interest & Investment Income | 74.9 | 74.88 | 58.34 | 18.03 | 10.48 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -11.4 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 9 | -4.67 | -38.22 | -2.06 | 11.85 | Upgrade
|
| EBT Excluding Unusual Items | 723.73 | 531.76 | 188.56 | 43.28 | -67.32 | Upgrade
|
| Merger & Restructuring Charges | -241.25 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 10 | - | 108 | - | Upgrade
|
| Other Unusual Items | - | - | - | -1.7 | -8.03 | Upgrade
|
| Pretax Income | 482.48 | 541.76 | 188.56 | 149.58 | -75.35 | Upgrade
|
| Income Tax Expense | 133.58 | 114.9 | 20.92 | 8.02 | -11.27 | Upgrade
|
| Net Income | 348.9 | 426.86 | 167.65 | 141.56 | -64.08 | Upgrade
|
| Net Income to Common | 348.9 | 426.86 | 167.65 | 141.56 | -64.08 | Upgrade
|
| Net Income Growth | -18.26% | 154.62% | 18.43% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 192 | 190 | 188 | 185 | 183 | Upgrade
|
| Shares Outstanding (Diluted) | 197 | 197 | 192 | 189 | 183 | Upgrade
|
| Shares Change (YoY) | 0.35% | 2.67% | 1.39% | 3.34% | -4.61% | Upgrade
|
| EPS (Basic) | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 | Upgrade
|
| EPS (Diluted) | 1.80 | 2.21 | 0.87 | 0.75 | -0.35 | Upgrade
|
| EPS Growth | -18.24% | 153.71% | 16.00% | - | - | Upgrade
|
| Free Cash Flow | 724.96 | 487.42 | 62.57 | 54.94 | 208.96 | Upgrade
|
| Free Cash Flow Per Share | 3.67 | 2.48 | 0.33 | 0.29 | 1.14 | Upgrade
|
| Gross Margin | 81.43% | 79.67% | 78.01% | 45.01% | 40.46% | Upgrade
|
| Operating Margin | 20.20% | 16.62% | 7.68% | 2.61% | -4.03% | Upgrade
|
| Profit Margin | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% | Upgrade
|
| Free Cash Flow Margin | 22.50% | 17.08% | 2.59% | 2.62% | 11.32% | Upgrade
|
| EBITDA | 722.89 | 570.64 | 290.16 | 156.65 | 33.72 | Upgrade
|
| EBITDA Margin | 22.44% | 19.99% | 11.99% | 7.47% | 1.83% | Upgrade
|
| D&A For EBITDA | 72.16 | 96.43 | 104.39 | 101.97 | 108.04 | Upgrade
|
| EBIT | 650.73 | 474.21 | 185.77 | 54.68 | -74.32 | Upgrade
|
| EBIT Margin | 20.20% | 16.62% | 7.68% | 2.61% | -4.03% | Upgrade
|
| Effective Tax Rate | 27.69% | 21.21% | 11.09% | 5.36% | - | Upgrade
|
| Revenue as Reported | 3,221 | 2,854 | 2,419 | 2,096 | 1,846 | Upgrade
|
| Advertising Expenses | 50.5 | 34.5 | 27.8 | 25.2 | 30.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.